A Randomized, Double-Blind, Placebo-Controlled Trial of the Human Anti-TNF-alfa Monoclonal Antibody Adalimumab for the Induction of Remission in Patients with Moderate to Severely Active Crohn´s Disease | Charles Explorer

A Randomized, Double-Blind, Placebo-Controlled Trial of the Human Anti-TNF-alfa Monoclonal Antibody Adalimumab for the Induction of Remission in Patients with Moderate to Severely Active Crohn´s Disease

Publication

Abstract

Crohn´s disease

People